PPD’s Lee Babiss Recognized for Innovation in CRO Services

Named to PharmaVOICE 100 List of Most Inspiring Leaders in Life Sciences Industry

PPD’s Lee Babiss Recognized for Innovation in CRO Services

PPD

Pharmaceutical Product Development, LLC () today announced that Lee Babiss, Ph.D., chief scientific officer and executive vice president of , has been named to the 2012 100 list of the most inspiring people in the life sciences industry.

The honor recognizes executives for their ability to influence corporate leadership, research and development, technology, creativity and strategy. magazine celebrated Dr. Babiss’ conviction and passion for innovation that sustain his ability to develop breakthrough strategies, products and services.

“Considered to be a true innovator, Dr. Lee Babiss is not interested in making small incremental changes, he is challenging himself and his teams to make leaps to find the disruptive technologies and bold solutions that will make a significant impact on how PPD provides services and value to clients and partners and, ultimately, how the company helps bring important medicines to patients," said Taren Grom, editor of . "Dr. Babiss’ achievements at PPD led to his recent promotion to chief scientific officer and being named to the 100."

After more than two decades in the biopharmaceutical industry, Dr. Babiss is helping lead PPD’s efforts to innovate to support biopharmaceutical partners in delivering life-changing therapies. His ultimate goal is to provide partners with novel solutions that drive program success and bring important medicines to patients.

“To be selected among the 100 industry leaders by is rewarding and energizing,” Dr. Babiss said. “While this is an individual honor, it is not an individual accomplishment. My colleagues at PPD deserve recognition for their dedication and forward-thinking approach to solving complex problems. At PPD, investing in talented people with extensive R&D expertise and utilizing transformational technologies are keys to meeting the needs of a partnering base that is emphasizing CRO relationships more than ever before.”

Prior to joining PPD, Dr. Babiss was president and director of pharmaceutical research for F. Hoffmann-La Roche Ltd., in Basel, Switzerland. Previously, he was vice president of preclinical research and development for Roche, based in Nultey, N.J. At GlaxoWellcome Inc., now GlaxoSmithKline, he held positions of increasing responsibility, including vice president of biological sciences and genetics.

The 100 is an annual list of individuals recognized for their positive contributions to the life sciences industry. Honorees are nominated by thousands of readers and represent a broad cross section of industry sectors. Those chosen contribute to the growth and well-being of their individual companies, their communities and varied industry associations.

PPD is a leading global providing , development and lifecycle management services. Our clients and partners include , , , academic and organizations. With offices in 46 countries and more than 12,000 professionals worldwide, PPD applies innovative technologies, and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit .

Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.